DE602007013762D1 - Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren - Google Patents

Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren

Info

Publication number
DE602007013762D1
DE602007013762D1 DE602007013762T DE602007013762T DE602007013762D1 DE 602007013762 D1 DE602007013762 D1 DE 602007013762D1 DE 602007013762 T DE602007013762 T DE 602007013762T DE 602007013762 T DE602007013762 T DE 602007013762T DE 602007013762 D1 DE602007013762 D1 DE 602007013762D1
Authority
DE
Germany
Prior art keywords
salt
büpyridin
compounds
allergic
pde4 inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007013762T
Other languages
English (en)
Inventor
David George Allen
Nicola Mary Aston
Rodger Phillip Barnett
Reshma Manesh Chudasama
Caroline Jane Day
Christopher David Edlin
Leanda Jane Kindon
Naimisha Trivedi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0615286A external-priority patent/GB0615286D0/en
Priority claimed from GB0706790A external-priority patent/GB0706790D0/en
Priority claimed from GB0714815A external-priority patent/GB0714815D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE602007013762D1 publication Critical patent/DE602007013762D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602007013762T 2006-08-01 2007-07-31 Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren Active DE602007013762D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0615286A GB0615286D0 (en) 2006-08-01 2006-08-01 Compounds
GB0706790A GB0706790D0 (en) 2007-04-05 2007-04-05 Compounds
GB0714815A GB0714815D0 (en) 2007-07-30 2007-07-30 Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors
PCT/GB2007/002908 WO2008015416A1 (en) 2006-08-01 2007-07-31 Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors

Publications (1)

Publication Number Publication Date
DE602007013762D1 true DE602007013762D1 (de) 2011-05-19

Family

ID=38996907

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007013762T Active DE602007013762D1 (de) 2006-08-01 2007-07-31 Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren

Country Status (18)

Country Link
US (3) US8003663B2 (de)
EP (1) EP2046787B1 (de)
JP (1) JP2009545579A (de)
AT (1) ATE504586T1 (de)
AU (1) AU2007280214A1 (de)
CA (1) CA2659539A1 (de)
CL (1) CL2007002349A1 (de)
CY (1) CY1111625T1 (de)
DE (1) DE602007013762D1 (de)
DK (1) DK2046787T3 (de)
HK (1) HK1127603A1 (de)
HR (1) HRP20110434T1 (de)
NZ (1) NZ574533A (de)
PL (1) PL2046787T3 (de)
PT (1) PT2046787E (de)
SI (1) SI2046787T1 (de)
TW (1) TW200840818A (de)
WO (2) WO2008015416A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003663B2 (en) * 2006-08-01 2011-08-23 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors
US8784847B2 (en) * 2009-04-17 2014-07-22 Merz Pharma Gmbh & Co. Kgaa Synthesis of 1-amino-1,3,3,5,5,-cyclohexane mesylate
UY33373A (es) 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
JP6062362B2 (ja) * 2010-08-19 2017-01-18 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Ｐｋｃ活性化剤を使用した、異常な樹状突起棘に関連した認知障害の治療
EP2628730B1 (de) * 2012-02-16 2017-12-06 Noxell Corporation Mehrstufige eintopfsynthese von salzen des 5-amino-4-nitroso-1-alkyl-1h-pyrazols
US9011934B2 (en) 2013-06-14 2015-04-21 SatisPharma, LLC Multi-purpose anti-itch treatment
US9452178B1 (en) 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
DE102015000626A1 (de) * 2015-01-22 2016-07-28 Kibion Gmbh Verfahren zum Nachweis von Helicobacter Pylori
CN111732543A (zh) * 2020-08-14 2020-10-02 浙江鼎龙科技有限公司 一种4,5-二氨基-1-（2-羟乙基）吡唑硫酸盐的制备方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200123A (en) 1962-01-26 1965-08-10 Richardson Merreil Inc Imidazoquinolines
JPS4824396B1 (de) 1970-09-09 1973-07-20
ZA81976B (en) 1980-02-15 1982-07-28 Glaxo Group Ltd Androstane carbothioates
DE3927761C2 (de) 1989-08-23 1997-11-27 Huels Chemische Werke Ag Verfahren zur Herstellung von Alkoxyalkylidenmalonsäureestern
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
EP0752853B1 (de) 1993-03-10 2005-09-21 Smithkline Beecham Corporation Phosphodiesterase des menschlichen gehirns
AU679511B2 (en) 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
WO1995034534A1 (en) 1994-06-15 1995-12-21 The Wellcome Foundation Limited Enzyme inhibitors
EP0832069B1 (de) 1995-06-07 2003-03-05 Pfizer Inc. Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
AR008234A1 (es) 1996-06-17 1999-12-29 Smithkline Beecham Plc Derivados de benzamidas, procedimiento para su preparacion, composiciones farmaceuticas y su uso para la preparacion de un medicamento
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
KR100568654B1 (ko) 1997-03-18 2006-04-07 스미스클라인비이참피이엘시이 치환된 이소퀴놀린 유도체 및 진경제로서의 그의 용도
AUPO622597A0 (en) 1997-04-15 1997-05-08 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
JPH11174621A (ja) 1997-10-08 1999-07-02 Fuji Photo Film Co Ltd 熱現像写真感光材料
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
SK284889B6 (sk) 1998-11-13 2006-02-02 Jago Research Ag Použitie stearátu horečnatého v suchých práškových formuláciách na inhaláciu
PT1158958E (pt) 1999-03-05 2007-08-13 Chiesi Farma Spa ''composições farmacêuticas em pó, melhoradas, para inalação''
DE60023128T2 (de) 1999-05-12 2006-07-06 Ortho-Mcneil Pharmaceutical, Inc. Pyrazolcarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
EP1218336A2 (de) 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Antagonisten des melanin-konzentrierenden hormons
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
NZ523526A (en) 2000-07-20 2004-10-29 Neurogen Corp Diaryl piperazines as capsaicin receptor ligands
AU7576001A (en) 2000-08-05 2002-02-18 Glaxo Group Ltd 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
US20020193393A1 (en) 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE365720T1 (de) 2001-03-08 2007-07-15 Glaxo Group Ltd Agonisten von beta-adrenorezeptoren
JP4143413B2 (ja) 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
ES2316599T3 (es) 2001-09-14 2009-04-16 Glaxo Group Limited Derivados de fenetanolamina para el tratamiento de enfermedades respiratorias.
GB0123951D0 (en) 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
GB0208608D0 (en) 2002-04-13 2002-05-22 Glaxo Group Ltd Composition
EP1497261B1 (de) 2002-04-25 2007-12-19 Glaxo Group Limited Phenethanolaminderivate
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
CA2497550A1 (en) 2002-09-16 2004-03-25 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
AU2003298094A1 (en) 2002-10-22 2004-05-13 Glaxo Group Limited Medicinal arylethanolamine compounds
DE60320007T2 (de) 2002-10-28 2009-06-18 Glaxo Group Ltd., Greenford Phenthanolamin-Derivate zur Behandlung von Atemwegserkrankungen
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
AP2007004238A0 (en) 2003-10-14 2007-12-31 Glaxo Group Ltd Muscarinic acetycholine receptor antagonists
PL1699512T3 (pl) 2003-11-03 2012-11-30 Glaxo Group Ltd Urządzenie do dozowania płynów
AR046225A1 (es) 2003-11-04 2005-11-30 Glaxo Group Ltd Compuesto de 8-azoniabiciclo(3.2.1)octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos que lo comprende y uso del compuesto para preparar dicha composicion
AU2004299277A1 (en) 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
JP2007529464A (ja) 2004-03-16 2007-10-25 グラクソ　グループ　リミテッド ビラゾロ［３，４−ｂ］ピリジン化合物及びＰＤＥ４阻害剤としてのその使用
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
JP2009510044A (ja) 2005-09-29 2009-03-12 グラクソ グループ リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物及びそのＰＤＥ４阻害薬としての使用
US8003663B2 (en) 2006-08-01 2011-08-23 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors

Also Published As

Publication number Publication date
JP2009545579A (ja) 2009-12-24
HRP20110434T1 (hr) 2011-08-31
CL2007002349A1 (es) 2008-10-10
EP2046787A1 (de) 2009-04-15
TW200840818A (en) 2008-10-16
US20090325952A1 (en) 2009-12-31
CA2659539A1 (en) 2008-02-07
HK1127603A1 (en) 2009-10-02
PT2046787E (pt) 2011-06-15
DK2046787T3 (da) 2011-07-18
WO2008015416A1 (en) 2008-02-07
AU2007280214A1 (en) 2008-02-07
PL2046787T3 (pl) 2011-10-31
US8003663B2 (en) 2011-08-23
EP2046787B1 (de) 2011-04-06
NZ574533A (en) 2011-05-27
SI2046787T1 (sl) 2011-07-29
WO2008015437A1 (en) 2008-02-07
US20090318494A1 (en) 2009-12-24
ATE504586T1 (de) 2011-04-15
CY1111625T1 (el) 2015-10-07
US20080058369A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
ATE504586T1 (de) Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren
TNSN08104A1 (en) Pyrimidine amide compounds as pgds inhibitors
EA200700219A1 (ru) ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНСУЛЬФАНИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 МАР КИНАЗЫ
DE60329193D1 (de) Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren
MX2009009443A (es) Compuestos de pirimidina hidrazida como inhibidores de pgds.
NO20063340L (no) Pyrazol-[3,4-B]-pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer
PT1252157E (pt) Carboxamidas de pirimidina uteis como inibidores de isozimas pde4
NO20084005L (no) Aminderivater
TW200500364A (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
ATE469159T1 (de) Substituierte oxadiazaspiro-ä5.5ü- undecanonderivate und ihre verwendung als neurokininantagonisten
ATE423779T1 (de) Hochselektiver rho-kinase-inhibitor
JP2011519845A5 (de)
UA93032C2 (uk) ПОХІДНІ ТРИАЗОЛОПІРИДИНІЛСУЛЬФАНІЛУ ЯК ІНГІБІТОРИ р38 MAP КІНАЗИ
DE602006016244D1 (de) Diazaspiro-ä4,4ü-nonanderivate als neurokinin-(nk1)-antagonisten
MX2008012634A (es) Derivados de piperidina utiles como inhibidores de transportador de serotonina y antagonistas del receptor neurokinina-1.
TH77766B (th) สารประกอบไพราโซโล [3,4-b]ไพริดีน, และการใช้พวกมันเสมือนเป็นตัวยับยั้งฟอสโฟไดเอสเทอเรส
PE20081835A1 (es) COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA Y SU USO COMO INHIBIDORES DE LA PDE4
NO20064806L (no) Formamidderivater anvendelige som adenoceptor
TH104555A (th) สารประกอบไพราโซโล[3,4-b]ไพริดีน และการใช้ของมันเป็นตัวยับยั้ง PDE4
TH87151A (th) สารประกอบเคมี
TH104555B (th) สารประกอบไพราโซล[3,4-b]ไพริดีน และการใช้ของมันเป็นตัวยับยั้ง PDE4
TH76965A (th) สารยับยั้งเอนไซม์ เคซีน ไคเนส ไอเอปซิลอน ชนิด 5- และ 6-อะมิโนอัลคิล อินโดล-2-กรดคาร์บอกซิลิค เอไมด์ ที่มีหมู่แทนที่ที่ตำแหน่ง 3 และอนาล็อกที่เทียบเคียงกัน
TH105528A (th) สารประกอบไพริมิดีน เอไมด์ ที่เป็นสารยับยั้งพรอสตาแกลนดิน
NO20063875L (no) Forbindelser som anvendes for behandling av sykdommer
TH105528B (th) สารประกอบไพริมิดีน เอไมด์ ที่เป็นสารยับยั้งพรอสตาแกลนดิน